Cenersen - University of Nebraska Medical Center
Alternative Names: Aezea; Cenersen sodium; EL625; EL831; OL(1)p53Latest Information Update: 02 Oct 2021
At a glance
- Originator University of Nebraska Medical Center
- Developer Eleos; H. Lee Moffitt Cancer Center and Research Institute
- Class Antineoplastics; Antisense oligonucleotides
- Mechanism of Action Tumour suppressor protein p53 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Myelodysplastic syndromes
- Discontinued Acute myeloid leukaemia; Chronic lymphocytic leukaemia
Most Recent Events
- 21 Feb 2021 Elos in collaboration with H.Lee Moffitt Cancer Center and Research Institute, terminates a phase I trial in Myelodysplastic syndromes in USA, as the company went out of business (NCT02243124)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes in USA (IV, Infusion)
- 01 Sep 2014 Phase-I clinical trials in Myelodysplastic syndromes in USA (IV)